
Me4BodipyFL-Ahx3Leu3VS
a fluorescent proteasome activity-based probe that can be used for accurate profiling of proteasome activity in cell lysates, intact cells, and murine and human patient-derived material
Additional information
| Weight | 0.05 kg |
|---|---|
| aliquot size | |
| Applications | Phenotypic protein profiling, Compound library screening, Target inhibitor profiling |
| target | |
| source | |
| shipping | |
| purity | |
| molecular weight | |
| storage | upon arrival, powder at +4°C; solution at −80°C. Please avoid multiple freeze/thaw cycles. |
| sample preparation | For detailed sample preparation see product sheet. |
| regulatory statement |
€380.00
- Description
- Additional information
- references
Description
Me4BodipyFL-Ahx3Leu3VS (UbiQ-018) is a fluorescent proteasome activity-based probe that can be used for accurate profiling of proteasome activity in cell lysates, intact cells, and murine and human patient-derived material, with high sensitivity using SDS-PAGE. The probe allows for direct scanning of the gel for fluorescent emission of the distinct proteasome subunits and circumvents the use of western-blot analysis. Due to its suitable biochemical and biophysical properties the fluorescent probe can also be used for confocal laser scanning microscopy and flow cytometry-based experiments.
Additional information
| Weight | 0.05 kg |
|---|---|
| aliquot size | |
| Applications | Phenotypic protein profiling, Compound library screening, Target inhibitor profiling |
| target | |
| source | |
| shipping | |
| purity | |
| molecular weight | |
| storage | upon arrival, powder at +4°C; solution at −80°C. Please avoid multiple freeze/thaw cycles. |
| sample preparation | For detailed sample preparation see product sheet. |
| regulatory statement |
-
UbiQ protocol P006: Fluorescence-based proteasome activity profiling
-
Berkers et al. Profiling proteasome activity in tissue with fluorescent probes. Mol Pharm 2007, 739, 739: http://www.ncbi.nlm.nih.gov/pubmed/17708652
-
Berkers et al. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib. Mol Pharm 2012, 9, 1126: http://www.ncbi.nlm.nih.gov/pubmed/22432738
